Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sz-Hao Chu
Observed name:
S. Chu
Institution:
Masonic Cancer Center
Observed institution:
Masonic Cancer Center
ORCID:
0009-0003-3740-3567
Observed ORCID:
0009-0003-3740-3567
OpenAlex ID:
A5031427713
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor
2022
·
Jia-Shiong Chen
, Cheng-Han Chou
, et al.
·
Scientific Reports
·
22
PDF
Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice
2022
·
Jia-Shiong Chen
, Yi-Chien Hsieh
, et al.
·
International Journal of Molecular Sciences
·
19
PDF
Combination therapy with IL-15 superagonist (ALT-803) and PD-1 blockade enhances human NK cell immunotherapy against ovarian cancer
2017
·
M.A. Geller
, L.A. Bendzick
, et al.
·
Gynecologic Oncology
·
9
Preclinical development of GNTbm-38, a novel class I histone deacetylase inhibitor, while combined with anti-VEGFR TKI or anti-PD-1 Ab: Assessment of immune activation and immune memory in cancer immunotherapy.
2025
·
Jia-Shiong Chen
, Cheng-Han Chou
, et al.
·
Journal of Clinical Oncology
·
1
PDF
GNTbm-38, a Novel Epigenetic Modulator, Performs Immune Activation and Reprogramming of the Tumor Microenvironment
2026
·
Chia-Nan Chen
, Cheng-Han Chou
, et al.
·
Molecular Cancer Therapeutics
PDF
Show more works
View as search
Works count:
5
Citation count:
51
H-index:
3
I10-index:
2
Year
Topic
Type